Congratulations to MEDCAPTAIN (Stock Code: 2041.HK) on the Successful IPO on the Main Board of the HKEX!

CR SWCS Team is honoured to serve as the ESG consultant of MEDCAPTAIN, committed to ensuring governance, compliance, and sustained growth.

COMPANY PROFILE

Medcaptain is a global medical device provider established in 2011, dedicated to delivering comprehensive clinical solutions across hospitals, community health centres, testing facilities and home care scenarios. The company's product portfolio comprises over 60 life support products, 110 minimally invasive intervention products, and 150 in vitro diagnostics products, available in multiple models to accommodate diverse application needs. Medcaptain’s products have cumulatively reached over 140 countries and regions globally. In China, its products have cumulatively reached over 6,000 hospitals, including approximately 90% of Grade 3A (三級甲等) hospitals, covering 31 provinces, municipalities and autonomous regions —a testament to the company's deep-rooted presence and extensive influence in the domestic medical device market.

Source: https://www.medcaptain.com